Fusion Antibodies (LON:FAB) Stock Price Down 3.4% – Here’s Why

Fusion Antibodies plc (LON:FAB) shares were down 3.4% during trading on Wednesday . The stock traded as low as GBX 14 and last traded at GBX 14. Approximately 225,728 shares traded hands during trading, a decline of 54% from the average daily volume of 491,605 shares. The stock had previously closed at GBX 14.50.

Fusion Antibodies Price Performance

The stock has a market capitalization of £17.85 million, a price-to-earnings ratio of -9.52 and a beta of 1.22. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The company has a 50 day moving average of GBX 13.16 and a 200 day moving average of GBX 13.77.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.